投融资数据库
免费查数据
注册送3天会员
首页>投融资
RevOpsis
未公开
RevOpsis Therapeutics, founded in 2022, is a biotechnology company focused on developing fully human, antibody-like proteins, using its Surrobody platform, for the potential treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, thyroid eye disease and other vascular eye diseases
基本信息
-
公司全称RevOpsis Therapeutics Inc
-
类型眼科疗法开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数不明确
-
地址4109 Chandlerwood SPRINGFIELD ILLINOIS 62711; US; Telephone: +16462215178;
-
联系电话
-
邮箱
-
成立时间2018-01-01
相关投融资企业
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
收并购
Kronos Bio, Inc.于2017年6月2日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，致力于发现和开发新的癌症疗法，旨在通过针对失调转录的精确药物策略来改变患者的预后。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息